Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
Status:
Completed
Trial end date:
2020-05-29
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of Chinese herbal formulation
PHY906 when given together with sorafenib tosylate in treating patients with advanced liver
cancer. Biological therapies, such as Chinese herbal formulation PHY906, may interfere with
the growth of tumor cells and slow the growth of tumors. Sorafenib tosylate may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib
tosylate may also stop the growth of liver cancer by blocking blood flow to the tumor. Giving
Chinese herbal formulation PHY906 together with sorafenib tosylate may work better in
treating advanced liver cancer.